MY162411A - Crystalline forms of a macrolide, and uses therefor - Google Patents

Crystalline forms of a macrolide, and uses therefor

Info

Publication number
MY162411A
MY162411A MYPI2012004183A MYPI2012004183A MY162411A MY 162411 A MY162411 A MY 162411A MY PI2012004183 A MYPI2012004183 A MY PI2012004183A MY PI2012004183 A MYPI2012004183 A MY PI2012004183A MY 162411 A MY162411 A MY 162411A
Authority
MY
Malaysia
Prior art keywords
crystalline forms
macrolide
uses therefor
therefor
preparing
Prior art date
Application number
MYPI2012004183A
Other languages
English (en)
Inventor
David E Pereira
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY162411(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of MY162411A publication Critical patent/MY162411A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MYPI2012004183A 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor MY162411A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22

Publications (1)

Publication Number Publication Date
MY162411A true MY162411A (en) 2017-06-15

Family

ID=44673574

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012004183A MY162411A (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Country Status (19)

Country Link
US (4) US8975386B2 (OSRAM)
EP (2) EP2550286B1 (OSRAM)
JP (4) JP5711352B2 (OSRAM)
KR (2) KR20180101643A (OSRAM)
CN (2) CN103080122A (OSRAM)
AU (2) AU2011232627B2 (OSRAM)
BR (1) BR112012023950A2 (OSRAM)
CA (1) CA2793884C (OSRAM)
DK (1) DK2550286T3 (OSRAM)
ES (1) ES2564097T3 (OSRAM)
HR (1) HRP20160168T1 (OSRAM)
IL (1) IL222018B (OSRAM)
MX (1) MX361413B (OSRAM)
MY (1) MY162411A (OSRAM)
NZ (1) NZ602544A (OSRAM)
PL (1) PL2550286T3 (OSRAM)
RU (1) RU2650883C2 (OSRAM)
SI (1) SI2550286T1 (OSRAM)
WO (1) WO2011119604A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
HRP20160222T1 (hr) 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
JP5711352B2 (ja) * 2010-03-22 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライドの結晶形、およびその使用
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
IN2014DN08939A (OSRAM) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CA2905975A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
MX377459B (es) 2013-04-04 2025-03-10 Harvard College Macrolidos y metodos para su preparacion y uso.
RU2017104163A (ru) * 2014-08-05 2018-09-06 Семпра Фармасьютикалз, Инк. Порошкообразные составы пероральных суспензий антибактериальных агентов
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
WO2016057798A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
WO2017061431A1 (ja) * 2015-10-05 2017-04-13 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
WO2021113357A1 (en) * 2019-12-02 2021-06-10 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ATE296308T1 (de) 1996-09-04 2005-06-15 Abbott Lab 6-o-substituierte ketoliden mit antibakteriellen wirkung
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
ID24529A (id) 1997-06-11 2000-07-20 Pfizer Prod Inc Turunan-turunan 9-oksima eritromisin
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
TR200102129T2 (tr) 1998-12-10 2002-01-21 Pfizer Products Inc. Karbamat ve karbazat ketolid antibiyotikleri.
KR20020002380A (ko) 1999-01-27 2002-01-09 실버스타인 아써 에이. 케톨라이드 항생물질
CA2292359C (en) 1999-01-28 2004-09-28 Pfizer Products Inc. Novel azalides and methods of making same
CN1373767A (zh) 1999-04-16 2002-10-09 奥索-麦克尼尔药品公司 酮式大环内酯抗菌剂
ATE340183T1 (de) 1999-04-16 2006-10-15 Kosan Biosciences Inc Antiinfektiöse makrolidderivate
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
WO2001068662A1 (en) * 2000-03-15 2001-09-20 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form ii crystals
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
ES2261735T3 (es) 2001-05-18 2006-11-16 Chiron Corporation Sistema para la administracion de una formulacion de tobramicina.
JP4509553B2 (ja) 2001-07-03 2010-07-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗菌活性を有するｃ１２修飾エリスロマイシンマクロライドおよびケトライド
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
MXPA04008173A (es) 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
DK2226316T3 (en) 2002-05-30 2016-04-11 Scripps Research Inst Copper catalyzed ligation of azides and acetylenes
US7091196B2 (en) 2002-09-26 2006-08-15 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP1638549A4 (en) * 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
EP1618120A2 (en) 2003-04-25 2006-01-25 Chiron Corporation Novel ketolide derivatives
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
EP1742957B1 (en) 2004-04-28 2007-09-12 Alembic Limited Process for the preparation of telithromycin
BRPI0513903A (pt) 2004-07-28 2008-05-20 Ranbaxy Lab Ltd derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
DK1836211T3 (da) * 2004-12-21 2010-05-17 Pfizer Prod Inc Makrolider
WO2006075256A2 (en) 2005-01-14 2006-07-20 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
WO2007059307A2 (en) * 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
WO2009053259A1 (en) 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
HRP20160222T1 (hr) * 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
JP5711352B2 (ja) * 2010-03-22 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライドの結晶形、およびその使用

Also Published As

Publication number Publication date
BR112012023950A2 (pt) 2016-07-05
CA2793884C (en) 2019-09-10
NZ602544A (en) 2014-11-28
ES2564097T3 (es) 2016-03-17
KR102006200B1 (ko) 2019-08-01
RU2650883C2 (ru) 2018-04-18
EP2550286A1 (en) 2013-01-30
JP2020002168A (ja) 2020-01-09
AU2011232627B2 (en) 2016-03-17
CN103080122A (zh) 2013-05-01
DK2550286T3 (en) 2016-02-29
PL2550286T3 (pl) 2016-07-29
EP3009442B1 (en) 2019-06-19
US20130252915A1 (en) 2013-09-26
AU2016203986B2 (en) 2016-10-06
CN108570083A (zh) 2018-09-25
KR20180101643A (ko) 2018-09-12
MX361413B (es) 2018-12-05
US20130018008A1 (en) 2013-01-17
JP2017081953A (ja) 2017-05-18
JP6121387B2 (ja) 2017-04-26
EP2550286B1 (en) 2015-12-09
WO2011119604A1 (en) 2011-09-29
CA2793884A1 (en) 2011-09-29
SI2550286T1 (sl) 2016-04-29
JP2013522367A (ja) 2013-06-13
US8975386B2 (en) 2015-03-10
KR20130056226A (ko) 2013-05-29
RU2012144614A (ru) 2014-04-27
AU2011232627A1 (en) 2012-10-18
IL222018B (en) 2019-05-30
MX2012010895A (es) 2013-02-15
AU2016203986A1 (en) 2016-06-30
HRP20160168T1 (hr) 2016-03-25
US8759500B2 (en) 2014-06-24
HK1177937A1 (en) 2013-08-30
EP3009442A1 (en) 2016-04-20
US20160244472A1 (en) 2016-08-25
JP2015063536A (ja) 2015-04-09
JP5711352B2 (ja) 2015-04-30
EP2550286A4 (en) 2013-10-02
US20190040096A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
IL216826A0 (en) Pyridil-triazine derivatives, compositions comprising the same and processes for producing the same
ZA201208198B (en) Picolinamide and pyrimidine-4-carboxamine compounds, process for preparing and pharmaceutical composition comprising the same
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
TW201144301A (en) Processes for preparing linezolid
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
HUE037747T2 (hu) Nanostrukturált aprepirant készítmények, eljárások azok elõállítására és az azokat tartalmazó gyógyászati készítmények
AP2011005935A0 (en) New Benzothiadiazepine compounds, a process for their preparation and pharmaceutical compositions comprising them.
WO2010117738A3 (en) Solid state forms of sitagliptin salts
LT3632448T (lt) Farmacinė kompozicija, apimanti drospirenoną, skirta naudoti kaip kontracepcija
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
ZA201108292B (en) New compounds,pharmaceutical composition and methods relating thereto
PL2531505T3 (pl) Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami
IN2012DN02793A (OSRAM)
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
PT2504331E (pt) Composto, novas formas desse composto, composições farmacêuticas desse composto e métodos de preparação e utilização
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
PH12013500210A1 (en) Highly crystalline valsartan
AP2012006645A0 (en) Pharmaceutical compositions comprising paracetamoland process for preparing the same
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.